Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2007 September;32(3) > Minerva Endocrinologica 2007 September;32(3):161-71

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA ENDOCRINOLOGICA

A Journal on Endocrine System Diseases


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,383


eTOC

 

  OBESITY IN 2007


Minerva Endocrinologica 2007 September;32(3):161-71

Copyright © 2007 EDIZIONI MINERVA MEDICA

language: English

Adipokines in diabetes and cardiovascular diseases

Kralisch S. 1, Sommer G. 1, Deckert C. M. 2, Linke A. 3, Bluher M. 1, 4, Stumvoll M. 1, 4, Fasshauer M. 1, 4

1 Department of Internal Medicine III University of Leipzig, Leipzig, Germany 2 Institute of Biochemistry University of Leipzig, Leipzig, Germany 3 Heart Center Department of Internal Medicine/Cardiology University of Leipzig, Leipzig, Germany 4 Interdisciplinary Center for Clinical Research Leipzig Leipzig, Germany


PDF  


Recent studies suggest that adipocyte-secreted factors called adipokines are involved in obesity-associated complications including hyperlipidemia, diabetes mellitus, arterial hypertension, atherosclerosis, and heart failure. Among those, adiponectin is an antidiabetic and antiatherogenic protein, concentrations of which are decreased in obesity-associated metabolic and vascular disorders. In contrast, leptin, tumor necrosis factor α, interleukin-6, monocyte chemoattractant protein-1, and plasminogen activator inhibitor-1 are upregulated in obesity and contribute to the development of diabetes and vascular disease. In this review, the relevance of adipokines in obesity, insulin resistance, diabetes mellitus, atherosclerosis, and cardiovascular diseases is discussed.

top of page

Publication History

Cite this article as

Corresponding author e-mail